替吉奥同步放化疗后单药序贯治疗老年进展期食管癌疗效观察  

Clinical Study of Chemoradiotherapy and Sequential Therapy with S1 for Elder Patients with Advanced Esophageal Cancer

作　　者：龙翔宇[1] 王兴远[1] 

机构地区：[1]四川省广安市人民医院肿瘤科,638001

出　　处：《医学理论与实践》2015年第1期8-10,共3页The Journal of Medical Theory and Practice

基　　金：四川省广安市科技资助项目

摘　　要：目的：探讨替吉奥同步放化疗后单药序贯治疗老年进展期食管癌的有效性及安全性。方法：对45例老年进展期食管癌患者,采用替吉奥,60-80mg/（m^2·d）,2次/d,连服14d,停药7d,21d为1个周期,共2周期,同步放疗54Gy/30f后,同方案的替吉奥化疗4-8周期或患者到不能耐受。结果：所有患者均可评价,CR：13例（28.9%）,PR：22例（48.9%）,SD：7例（15.6%）。中位PFS为8.0个月。1、2年生存率分别为：60.0%、22.2%,中位生存时间：13.5个月。骨髓抑制发生率高但易于处理。结论：替吉奥同步放化疗后序贯单药化疗治疗老年进展期食管癌效果较好,副反应可以耐受,但需随机对照试验验证。Objective：To evaluate the efficacy and adverse reaction of chemoradiotherapy and sequential therapy with S-1for elder patients with advanced esophageal cancer.Methods：Total of 45 elder patients with advanced esophageal cancer received S-1two cycles,60-80mg/（m^2·d）,on days 1-14every 21 days as a cycle,combined with 3Dconformal radiation therapy with DT：54Gy/30 f.Then,S-1was followed by same dose 4-8cycle or patients intolerance.Results：All the patients could be evaluated.There were 13（28.9%）patients with complete response,22（48.9%）patients with partial response,7（15.6%）patients with v stable disease.The median progression-free survival time was 8.0months.The 1-,2-year survival rates were 60.0% and 22.2%,respectively.The median survival time was 13.5months.The main toxicities were myelosuppression,but easily manage.Conclusion：S-1followed chemoradiotherapy was efficacy and toxicity was tolerable to elder patients with advanced esophageal cancer.But need randomized controlled trials to confirm.

关 键 词：食管癌 三维适形治疗 替吉奥 化疗 

分 类 号：R735.1[医药卫生—肿瘤]